Trial Profile
Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Pharmacodynamics; Registrational
- Acronyms ZOSTER-060 EXT:003
- Sponsors GlaxoSmithKline; GSK
- 08 Dec 2018 Status changed from active, no longer recruiting to completed.
- 24 Oct 2018 This trial has been completed in Sweden (End date: 2018-10-08).
- 20 Oct 2018 This trial has been completed in Germany.